Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Bryan R. Leigh"'
Autor:
Yin Zhang, Hao Hong, Jonathan W Engle, Jero Bean, Yunan Yang, Bryan R Leigh, Todd E Barnhart, Weibo Cai
Publikováno v:
PLoS ONE, Vol 6, Iss 12, p e28005 (2011)
Optimizing the in vivo stability of positron emission tomography (PET) tracers is of critical importance to cancer diagnosis. In the case of (64)Cu-labeled monoclonal antibodies (mAb), in vivo behavior and biodistribution is critically dependent on t
Externí odkaz:
https://doaj.org/article/f2f2092e375f40c886e9c8248d0e1c22
Autor:
Jonathan H. Goldman, Michael S. Gordon, Shawn D. Spencer, Bryan R. Leigh, William D. Figg, Herbert Hurwitz, Ben K. Seon, Charles P. Theuer, David S. Mendelson, Bonne J. Adams, Lee S. Rosen, Michael K. Wong, Delia Alvarez
Publikováno v:
Clinical Cancer Research. 18:4820-4829
Purpose: TRC105 is a chimeric IgG1 monoclonal antibody that binds CD105 (endoglin). This first-in-human, phase I, open-label study assessed safety, pharmacokinetics, and antitumor activity of TRC105 in patients with advanced refractory solid tumors.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c3a8ccb9dc1771e90f3c1665661858d
https://doi.org/10.1158/1078-0432.ccr-12-0098
https://doi.org/10.1158/1078-0432.ccr-12-0098
Autor:
Yin Zhang, Yunan Yang, Hao Hong, Weibo Cai, Todd E. Barnhart, Jonathan W. Engle, Bryan R. Leigh, Robert J. Nickles
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging. 38:1335-1343
Overexpression of CD105 (endoglin) correlates with poor prognosis in many solid tumor types. Tumor microvessel density (MVD) assessed by CD105 staining is the current gold standard for evaluating tumor angiogenesis in the clinic. The goal of this stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8493a82536a2a427b8e9d2123fb88e5
https://doi.org/10.1007/s00259-011-1765-5
https://doi.org/10.1007/s00259-011-1765-5
Autor:
James Woodworth, Ian W. Flinn, Thomas S. Lin, Dee Wynne, Sarah Harris, Mark Weiss, Bryan R. Leigh, Susan O'Brien, Jennifer Reid, John C. Byrd, Kanti R. Rai, Thomas J. Kipps, Arturo Molina
Publikováno v:
Clinical Cancer Research. 13:4448-4455
Purpose: Therapeutic antibodies have improved the outcome for patients with chronic lymphocytic leukemia (CLL). We conducted a phase 1, dose escalation and schedule optimization study of the primatized anti-CD23 antibody, lumiliximab, in patients wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddd1ef83ae9bfb86405d37e9af0d59b6
https://doi.org/10.1158/1078-0432.ccr-06-1463
https://doi.org/10.1158/1078-0432.ccr-06-1463
Autor:
Kari Chansky, Derick H Lau, Antoinette J. Wozniak, Bryan R. Leigh, Geoffrey R. Weiss, John Crowley, Laurie E. Gaspar, David R. Gandara, Angela M. Davies
Publikováno v:
Journal of Clinical Oncology. 24:5242-5246
Purpose A previous Southwest Oncology Group (SWOG) study (S9429) demonstrated efficacy and tolerability of concurrent chemoradiotherapy in poor-risk stage III non–small-cell lung cancer (NSCLC). This study evaluated adding consolidation paclitaxel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90e6f9a073ad57e07d978ea3224ee117
https://doi.org/10.1200/jco.2006.07.0268
https://doi.org/10.1200/jco.2006.07.0268
Autor:
Geoffrey R. Weiss, Bryan R. Leigh, Martin J. Edelman, David R. Gandara, Laurie E. Gaspar, Robert B. Livingston, Sarah A. Taylor, John Crowley, Kari Chansky
Publikováno v:
Journal of Clinical Oncology. 22:127-132
Purpose Limited small-cell lung cancer (LSCLC) is characterized by a high initial response rate to chemoradiotherapy, but local or systemic relapse occurs in the majority of patients. Previous Southwest Oncology Group trials in LSCLC have utilized ci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c85ab278de882c78e2d8d4009dad9ce1
https://doi.org/10.1200/jco.2004.06.070
https://doi.org/10.1200/jco.2004.06.070
Autor:
Kari Chansky, Bryan R. Leigh, James D. Bearden, Primo N. Lara, Kathy S. Albain, David R. Gandara, Laurie E. Gaspar, Robert B. Livingston, Howard Burris, J. Philip Kuebler, John Crowley, Paul H. Gumerlock
Publikováno v:
Journal of Clinical Oncology. 21:2004-2010
Purpose: To test the concept of taxane sequencing in combined-modality therapy, this phase II trial (S9504) evaluated consolidation docetaxel after concurrent chemoradiotherapy in patients with pathologically documented stage IIIB non–small-cell lu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff5bf4e25d092754f41420527f98c5b9
https://doi.org/10.1200/jco.2003.04.197
https://doi.org/10.1200/jco.2003.04.197
Autor:
Angela Hong, Bryan R. Leigh
Publikováno v:
Chemotherapy. 48:238-243
Background: Kaposi’s sarcoma (KS) is the most common neoplastic apoptosis manifestation of acquired immunodeficiency syndrome. Toremifene is known to upregulate transforming growth factor beta-1 (TGF-β1), which is a growth-inhibitory factor for KS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37be0f2543a8106bec94921252780993
https://doi.org/10.1159/000066765
https://doi.org/10.1159/000066765
Autor:
Derick H Lau, David R. Gandara, Bryan R. Leigh, Primo N. Lara, Richard B. Wilder, Martin J. Edelman, James Doroshow, Robert J. Morgan, J. Ryu, Valerie Israel
Publikováno v:
Journal of Clinical Oncology. 19:442-447
PURPOSE: Recent studies have suggested the superiority of concurrent chemoradiotherapy and the efficacy of paclitaxel/carboplatin in advanced non–small-cell lung cancer (NSCLC). In view of those results, we sought to examine the safety and efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65df349033df4ed8180a55b39e90d74c
https://doi.org/10.1200/jco.2001.19.2.442
https://doi.org/10.1200/jco.2001.19.2.442
Neovascular Targeting with Cyclic RGD Peptide (cRGDf-ACHA) to Enhance Delivery of Radioimmunotherapy
Autor:
Kathleen R. Lamborn, Patricia A. Burke, Laird Miers, Sally J. DeNardo, Siegfried Matzku, Alfred Jonczyk, Linda A. Kroger, Gerald L. DeNardo, Simon L. Goodman, Bryan R. Leigh, Robert T. O'Donnell
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 15:71-79
Radioimmunotherapy (RIT) has been hampered by delivery of only a small fraction of the administered dose of radiolabeled MAb to tumor. A strategy for creating and controlling tumor vascular permeability would enable more effective RIT. The alpha v be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8468e46be58a3b20bba3e2f4e715f4a
https://doi.org/10.1089/cbr.2000.15.71
https://doi.org/10.1089/cbr.2000.15.71